Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914250 | 1.00 | LMNA (0.42) | LMNACYP2C9CA1CA9LNPEP | |
| SCHEMBL29914261 | 1.00 | LMNA (0.42) | LMNACYP2C9CA1CA9LNPEP | |
| SCHEMBL23043822 | 1.00 | LMNA (0.42) | LMNACYP2C9CA1CA9LNPEP | |
| SCHEMBL28520435 | 0.90 | LMNA (0.47) | LMNACYP2C9CA1CA9 | |
| SCHEMBL29914256 | 0.87 | LMNA (0.38) | LMNACYP2C9CA1CA9 | |
| SCHEMBL27678854 | 0.81 | LMNA (0.38) | LMNACYP2C9 | |
| SCHEMBL18407144 | 0.79 | LMNA (0.39) | LMNACYP2C9 | |
| SCHEMBL18407146 | 0.78 | LMNA (0.38) | LMNACYP2C9 | |
| SCHEMBL18407150 | 0.77 | LMNA (0.37) | LMNACYP2C9 | |
| SCHEMBL8611928 | 0.76 | TSHR (0.35) | LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025091000-A1 | BIODEGRADABLE NANOCOMPOSITE INK FOR 3D PRINTING RADIOPAQUE SCAFFOLDS | NORTHWESTERN UNIVERSITY (US) | 2025-05-01 | — | — | WO | disclosed |
| US-11850328-B2 | Body temperature-triggered, in situ forming biomaterials and devices | NORTHWESTERN UNIVERSITY (US) | 2023-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850328-B2 | Body temperature-triggered, in situ forming biomaterials and devices | BMP2, LRBA, BMP1 | LMNA 873/4885CYP2C9 623/4885CA1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.